$HALO Form 8-K




Change in Directors or Principal Officers, Financial Statements and Exh

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.(d) On August 5, 2015, Jeffrey W. Henderson was elected to the Board of Directors Halozyme Therapeutics, Inc. (the “Company”). Mr. Henderson was elected to the class of directors with terms ending in 2016 and will stand for election to the Board by the Company’s stockholders at the Company’s 2016 annual meeting of stockholders. Mr. Henderson will serve on the Board of Directors’ Audit Committee. Mr. Henderson will receive compensation for his services (currently consisting of cash retainers for Board and committee service and restricted stock awards) under our director compensation program applicable to all non-employee directors. The components of the non-employee director compensation program were described in our proxy statement for the 2015 Annual Meeting of Stockholders held on May 6, 2015. Under the director compensation program, on August 5, 2015, Mr. Henderson was granted 6,405 shares of restricted stock, representing a pro rata portion of the value of a restricted stock award for a full year of service on the Board of Directors.

There are no arrangements or understandings pursuant to which Mr. Henderson was elected as a director and there are no related party transactions between the Company and Mr. Henderson.

On August 5, 2015, the Company issued a press release announcing the election of Mr. Henderson to the Company’s Board of Directors. A copy of the press release is attached hereto as Exhibit 99.1.


Item 9.01 Financial Statements and ExhibitsExhibit No. Description

99.1 Press Release dated August 5, 2015


Please enter your comment!
Please enter your name here